| Returns | 1W : 12.1% , 1M : 26.6%,1Y : 64.2% |
| Peers & Returns | 1W | 1M | 1Y |
| NATCO PHARMA | 12.1% | 26.6% | 64.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -8.2% | 18.2% |
| DRREDDYS LABORATORIES | -0.3% | 19.4% | 84.3% |
| DIVIS LABORATORIES | -2.6% | -1.7% | 91.9% |
| CIPLA | -0.6% | 7% | 72.6% |
| PIRAMAL ENTERPRISES | 1.3% | -8.3% | -29.6% |
| LUPIN | -1.8% | 7.6% | 37.6% |
| AUROBINDO PHARMA | 2% | -1.6% | 30.6% |
| TORRENT PHARMACEUTICALS | 2% | 1.9% | 57% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
27.84 5.21 9.35 - |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
58% 44% 57% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2019 2018 2017 Avg_3yrs |
0.11 0.06 0.13 0.1 |
0.11 0.06 0.14 0.1 |
|
[Last Annual Data : Mar2019]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
26.68% 22.46% 30.43% 25.45% |
14.53% -10.92% -14.18% -14.22% |
| QtrlyTrend |
2
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
